Evidence map›Paper›PMID 39589586›Full record

ReviewDiscover oncology2024

Advances in irreversible electroporation for prostate cancer.

Xinyu Liu, Hao Wang, Zilin Zhao, Qikai Zhong, Xinlei Wang, Xing Liu, Junzhi Chen, Conghui Han, Zhenduo Shi, Qing Liang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xinyu LiuXuzhou Clinical College of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Hao WangDepartment of Urology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
Zilin ZhaoXuzhou Clinical College of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Qikai ZhongXuzhou Clinical College of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Xinlei WangXuzhou Clinical College of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Xing LiuSoutheast University, Nanjing, Jiangsu, China.
Junzhi ChenXuzhou Clinical College of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Conghui HanXuzhou Clinical College of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Zhenduo ShiXuzhou Clinical College of Xuzhou Medical University, Xuzhou, Jiangsu, China. 156675834@qq.com.
Qing LiangXuzhou Clinical College of Xuzhou Medical University, Xuzhou, Jiangsu, China. liangqing1@163.com.

Funding

General Program State Administration of Traditional Chinese Medicine of Jiangsu MS2023081Key project of Jiangsu Provincial Health Commission K2023041National Key Research and Development Program of China 2023YFC2413403National Natural Science Foundation of China 82004110
6 · The paper itself

Abstract

Irreversible electroporation is a nonthermal ablation technique that uses a high-voltage electric current to create nanosized pores in the cell membrane of a malignant tumor, thus resulting in cell death. In recent years, an increasing number of clinical studies have shown that irreversible electroporation is a safe and effective treatment for prostate cancer. We describe the progress of irreversible electroporation in prostate cancer in recent years in terms of its mechanism of action, clinical studies, advantages and disadvantages and summarize the gaps in existing studies and directions for future research.

Indexed as

Irreversible electroporationLocal treatmentPhysical ablationProstate cancer

Identifiers

PMID39589586
PMCPMC11599553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.